Phase 1 Type 2 Diabetes Trial, Recruiting NCT05826054 Sponsor: Robert Petrella Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 1 Type 2 Diabetes Trial, Recruiting

NCT05826054
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 19 to 65 years old (male or female)
  • People who have been diagnosed with type 2 diabetes, with a blood sugar control reading (HbA1c) between 6.5% and 11%, managed through diet alone with no diabetes medications — or people who do not have type 2 diabetes at all (healthy volunteers)
  • People who follow regular eating habits that include three meals a day
  • People whose blood test results fall within the normal range, as assessed at a screening visit (healthy volunteers must have an HbA1c above 4.0%)
  • People who are using a reliable barrier method of contraception, have had a sterilisation procedure, or have been through menopause for at least 2 years
  • People who, in the study team's opinion, can understand and follow the visit schedule and study treatment instructions
  • People who are able to avoid taking supplements that may affect blood sugar levels for the entire duration of the study (examples include chromium, bitter melon, berberine, cinnamon, ginseng, fenugreek, garlic, and others — confirm full list with trial site)

Who may not be able to join:

  • People who are currently in poor health, as assessed by the study doctor
  • People who are currently taking any medications, other than vitamins or birth control
  • People who do not eat three regular meals a day
  • People who have a current or past condition affecting the stomach or intestines, such as inflammatory bowel disease, ulcers in the colon, or a partial blockage in the intestine
  • People who have travelled to another country within the four weeks before the study starts
  • People who have had surgery within the four weeks before the study starts
  • People who are pregnant or currently breastfeeding
  • People who plan to take part in another clinical drug trial at the same time as this study
  • People with a known allergy to the study medication or any of its ingredients
  • People who have a history of not following medical instructions, or who are unwilling or unable to attend all required study visits

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Robert Petrella, MD, PhD, University of British Columbia

Phone: 604-875-5886

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Robert Petrella
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
1 February 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Maximum tolerated dose (MTD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov